The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Thermo Fisher Scientific for two new COVID-19 tests, TaqPath COVID-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19 RNase P Combo Kit 2.0.
The Thermo Fisher tests are intended to address emerging mutations and variants, the company said. Both target eight genes across three regions of SARS-CoV-2.
TaqPath COVID-19 Fast PCR Combo Kit 2.0 tests saliva samples, while TaqPath COVID-19 RNase P Combo Kit 2.0 tests nasal samples, according to Thermo Fisher.
